Clinical Trials Sponsored by Orexigen Therapeutics, Inc

Total 2963 results

Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

Obesity | Overweight | Nicotine Dependence

United States
Orexigen Therapeutics, Inc

Completed

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

Obesity

United States
Orexigen Therapeutics, Inc

Terminated

Naltrexone/Bupropion Cardiovascular Outcomes Study

Cardiovascular Diseases | Obesity

United States
Orexigen Therapeutics, Inc

Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Heart Repolarization

United States
Orexigen Therapeutics, Inc

Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

Healthy Subjects
Orexigen Therapeutics, Inc

Completed

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

Obesity

United States
Orexigen Therapeutics, Inc

Completed

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Obesity

United States
Orexigen Therapeutics, Inc

Terminated

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

Healthy

United States
Orexigen Therapeutics, Inc

Completed

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight

United States
Orexigen Therapeutics, Inc

Terminated

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder

United States
Orexigen Therapeutics, Inc

Terminated

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder

United States
Orexigen Therapeutics, Inc

Completed

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

Depression

United States
Orexigen Therapeutics, Inc

Completed

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

Obesity

United States
Oslo University Hospital
Orexigen Therapeutics, Inc

Withdrawn

Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery

Obesity
Brexogen Inc.

Recruiting

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States
Brexogen Inc.

Not yet recruiting

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Precigen, Inc

Recruiting

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Precigen, Inc

Recruiting

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Stage III Fallopian Tube... and other conditions

United States
Apexigen America, Inc.

Completed

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Melanoma | Cancer | Head and Neck Cancer | NSCLC | Urothelial Carcinoma | MSI-H

United States
Apexigen America, Inc.

Terminated

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Melanoma | Cancer | Metastatic Melanoma | Melanoma (Skin) | Unresectable Melanoma | Cancer of Skin

Spain, Poland
Apexigen America, Inc.

Completed

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Esophageal Cancer | GastroEsophageal Cancer

United States
Yale University
Apexigen America, Inc.

Recruiting

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Advanced Melanoma

United States
Apexigen America, Inc.
Bristol-Myers Squibb

Completed

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Melanoma | Cancer | Metastatic Melanoma | Non Small Cell Lung Cancer Metastatic | Neoplasm of Lung

United States, Spain
BioNTech US Inc.
Apexigen, Inc.

Terminated

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Metastatic Melanoma

United States
Precigen, Inc
National Cancer Institute (NCI)

Recruiting

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical Cancer | HPV-Related Malignancy | HPV-Related Carcinoma

United States
Precigen, Inc
National Cancer Institute (NCI)

Active, not recruiting

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

Papillomavirus Infections | Recurrent Respiratory Papillomatosis | Papillomaviridae

United States
Triple-Gene, LLC
Intrexon Corporation; Precigen, Inc

Completed

Novel INXN-4001 Triple Effector Plasmid in Heart Failure

Cardiovascular Diseases | Heart Failure | Heart-Assist Device

United States
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Tinea Pedis | Tinea Cruris

United States
Therapeutics, Inc.

Completed

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

Scalp Psoriasis

United States
Therapeutics, Inc.

Completed

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Tinea Pedis

United States, Puerto Rico
Therapeutics, Inc.

Completed

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Plaque Psoriasis

United States, Georgia, Ukraine
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

Plaque Psoriasis

United States

3

Subscribe